Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. It offers ImmunoINSIGHTS, an autoantibody profiling service that unlocks the immune system to discover and convert autoantibodies into actionable biomarkers; Sero Tag, a discovery engine which identifies relevant biomarker pool for target discovery or companion diagnostics; NavigAID, a creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. The company also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.